Rise in cases of fibromyalgia is responsible for the growth of fibromyalgia treatment market. The pain that is linked with fibromyalgia is generally described as a continuous dull ache that has lasted for atleast 90 days.
To be categorized as ‘widespread’, pain should be visible on both the sides of the body, i.e. below and above the waist. Several drugs in pipeline are another factor expanding the market size.
The companies operating in fibromyalgia treatment market are working toward incorporation of hyperbaric oxygen therapy and comparing it with pharmacological intervention in the adults diagnosed with fibromyalgia, especially the one pertaining to childhood sexual abuse. Randomized, prospective clinical trials are thus on the anvil.
Fibromyalgia is referred to as a disorder characterized by severe musculoskeletal pain followed by fatigue, and issues related to memory, mood, and fatigue. Research states that fibromyalgia raises painful sensations by adversely affecting the way spinal cord and brain process non-painful and painful signals.
Symptoms generally show up after an event such as surgery, physical trauma, notable psychological stress or infection. Women are at a higher risk of developing fibromyalgia than men. Majority of people having fibromyalgia also suffer from tension headaches, temporomandibular joint (TMJ) disorders, depression, anxiety, and irritable bowel syndrome.
Though there are no prescribed therapeutics available for fibromyalgia, various medications can help in controlling symptoms. Stress-reduction measures, relaxation, and exercise may also assist.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
As per the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), close to 5 million individuals aged 18 and above suffer from fibromyalgia in the U.S. IT further states that more than 80-90% of fibromyalgia patients are females.
Furthermore, the governments are taking initiatives in order to guide healthcare professionals and manufacturers with respect to fibromyalgia. For instance, the European League Against Rheumatism (EULAR) issued a recommendation during 2016 guidelines against usage of non-steroidal anti-inflammatory drugs (NSAID) for treating fibromyalgia.
These policies are expected to boost awareness and help in managing fibromyalgia amongst the affected population. Need to combat fibromyalgia is thus accelerating the fibromyalgia treatment market demand.
The key players are at the forefront regarding the introduction of innovative medications for treatment of fibromyalgia to continue with their foothold in the fibromyalgia treatment market.
For instance, in January 2021, Eli Lily and Company’s Galcanezumab was bound to enter its pivotal clinical end-stage in December 2021 for treating fibromyalgia. It was approved for cluster headache and migraine prior to that.
In May 2022, Scilex Holding Company announced its phase 1 clinical trial results for SP-104 for fibromyalgia treatment industry. SP-104 is a proprietary, new, fixed dose, delayed burst release of low dose naltrexone hydrochloride, 4.5 mg, to treat fibromyalgia.
The phase 1 data showed that SP-104 treated healthy volunteers and had comparatively lower rates of the adverse events in comparison with immediate release naltrexone-treated volunteers.
Noticeable pipeline of products is thus driving the fibromyalgia treatment market opportunities.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest fibromyalgia treatment market analysis, North America held the largest share in the fibromyalgia medication landscape in 2023 and the scenario is expected to remain the same during the forecast period.
This is attributed to rise in the number of patients in the U.S. living with fibromyalgia coupled with conducive reimbursement policies by the government.
Therefore, patients are encouraged to seek as well as maintain medication-based fibromyalgia management. The generic manufacturers are also strengthening their presence by introducing affordable generics of well-known brands.
Asia Pacific’s fibromyalgia treatment market growth is ascribed to improving healthcare infrastructure in countries such as India and China. While generic drug makers in China and India have raised exports volumes, various large pharmaceutical companies have made an entry into the market through collaborations with local players.
The key players in fibromyalgia treatment market are banking on the research findings by universities and research institutes to strengthen their position. For instance, in February 2022, Karabuk University (Turkey) conducted research on wet cupping therapy (WCT) in collaboration with SUELYMAN ERSOY, Saglik Bilimleri University.
Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Tonix Pharmaceuticals, Aptinyx Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Limited, Astellas Pharma Inc., ad Nipro Corporation are some of the key players covered in the fibromyalgia treatment market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 1.9 Bn |
| Market Forecast (Value) in 2034 | US$ 2.9 Bn |
| Growth Rate (CAGR) | 3.8% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 1.9 Bn in 2023
It is projected to grow at a CAGR of 3.8% from 2024 to 2034
Growing prevalence of fibromyalgia and robust pipeline of products
Retail pharmacies segment accounted for the largest share in 2023
North America was the dominant region in 2023
Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Tonix Pharmaceuticals, Aptinyx Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Limited, Astellas Pharma Inc., and Nipro Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fibromyalgia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fibromyalgia Treatment Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Fibromyalgia Treatment Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2017-2031
6.3.1. Medications
6.3.1.1. Pain Relievers
6.3.1.2. Anti-Depressants
6.3.1.3. Anti-Seizure Drugs
6.3.2. Therapies
6.3.2.1. Physical Therapy
6.3.2.2. Occupational Therapy
6.3.2.3. Counselling
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Fibromyalgia Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2017-2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Fibromyalgia Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Fibromyalgia Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment Type, 2017-2031
9.3.1. Medications
9.3.1.1. Pain Relievers
9.3.1.2. Anti-Depressants
9.3.1.3. Anti-Seizure Drugs
9.3.2. Therapies
9.3.2.1. Physical Therapy
9.3.2.2. Occupational Therapy
9.3.2.3. Counselling
9.4. Market Value Forecast, by Distribution Channel, 2017-2031
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Market Value Forecast, by Country, 2017-2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment Type
9.6.2. By Distribution Channel
9.6.3. By Country
10. Europe Fibromyalgia Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2017-2031
10.3.1. Medications
10.3.1.1. Pain Relievers
10.3.1.2. Anti-Depressants
10.3.1.3. Anti-Seizure Drugs
10.3.2. Therapies
10.3.2.1. Physical Therapy
10.3.2.2. Occupational Therapy
10.3.2.3. Counselling
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Distribution Channel
10.6.3. By Country/Sub-region
11. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2017-2031
11.3.1. Medications
11.3.1.1. Pain Relievers
11.3.1.2. Anti-Depressants
11.3.1.3. Anti-Seizure Drugs
11.3.2. Therapies
11.3.2.1. Physical Therapy
11.3.2.2. Occupational Therapy
11.3.2.3. Counselling
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Distribution Channel
11.6.3. By Country/Sub-region
12. Latin America Fibromyalgia Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2017-2031
12.3.1. Medications
12.3.1.1. Pain Relievers
12.3.1.2. Anti-Depressants
12.3.1.3. Anti-Seizure Drugs
12.3.2. Therapies
12.3.2.1. Physical Therapy
12.3.2.2. Occupational Therapy
12.3.2.3. Counselling
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Distribution Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2017-2031
13.3.1. Medications
13.3.1.1. Pain Relievers
13.3.1.2. Anti-Depressants
13.3.1.3. Anti-Seizure Drugs
13.3.2. Therapies
13.3.2.1. Physical Therapy
13.3.2.2. Occupational Therapy
13.3.2.3. Counselling
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Distribution Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Pfizer Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. AbbVie Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Tonix Pharmaceuticals
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Aptinyx Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Teva Pharmaceutical Industries Ltd.
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Novartis AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Sun Pharmaceutical Industries Limited
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Astellas Pharma Inc.
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Nipro Corporation
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
List of Tables
Table 01: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 02: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 03: Global Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Region, 2017-2031
Table 04: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country, 2017-2031
Table 05: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 06: North America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 07: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 08: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 09: Europe Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 10: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 12: Asia Pacific Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 13: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 15: Latin America Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
Table 16: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Treatment Type, 2017-2031
Table 18: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast, by Distribution Channel, 2017-2031
List of Figures
Figure 01: Global Fibromyalgia Treatment Market Size (US$ Bn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Fibromyalgia Treatment Market Revenue (US$ Bn), by Treatment Type, 2022
Figure 03: Global Fibromyalgia Treatment Market Value Share, by Treatment Type, 2022
Figure 04: Global Fibromyalgia Treatment Market Revenue (US$ Bn), by Distribution Channel, 2022
Figure 05: Global Fibromyalgia Treatment Market Value Share, by Distribution Channel, 2022
Figure 06: Global Fibromyalgia Treatment Market Value Share, by Region, 2022
Figure 07: Global Fibromyalgia Treatment Market Value (US$ Bn) Forecast, 2023-2031
Figure 08: Global Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 09: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 10: Global Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 11: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 12: Global Fibromyalgia Treatment Market Value Share Analysis, by Region, 2022 and 2031
Figure 13: Global Fibromyalgia Treatment Market Attractiveness Analysis, by Region, 2023-2031
Figure 14: North America Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 15: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Country, 2023-2031
Figure 16: North America Fibromyalgia Treatment Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 18: North America Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 19: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 20: North America Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 21: Europe Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 22: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 23: Europe Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 25: Europe Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 26: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 27: Europe Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 28: Asia Pacific Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 29: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 30: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 31: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 32: Asia Pacific Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 34: Asia Pacific Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 35: Latin America Fibromyalgia Treatment Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 36: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 37: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 38: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 39: Latin America Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 40: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 41: Latin America Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 42: Middle East & Africa Fibromyalgia Treatment Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 43: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 44: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 45: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Treatment Type, 2022 and 2031
Figure 46: Middle East & Africa Fibromyalgia Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 47: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Treatment Type, 2023-2031
Figure 48: Middle East & Africa Fibromyalgia Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Fibromyalgia Treatment Market
